Updates: Company News - Page 3
NB secures £2M investment from NVM Private Equity & Northstar Ventures to accelerate hiPSC growth
Founded on the technology of Prof Lyle Armstrong and Prof Majlinda Lako from Newcastle University, the company is at the forefront of the production and differentiation of human induced…
Read update
17th Annual World Preclinical Congress – Boston, MA (18th-21st June)
Dr Brown is the developer of the aProximateTM assay for measuring kidney transporter and nephrotoxicity licensed exclusively to Newcells Biotech. The World Preclinical Congress is a key networking event focusing on…
Read update
FMS Post-Doc Symposium 2018 – Newcastle University (15th June 2018)
Dr Chichagova will be talking about Retinitis Pigmentosa, one of the most common forms of inherited blindness affecting over 1 million people worldwide.With no effective treatment available for Retinitis…
Read update
Dr Chichagova awarded best In Vitro Toxicology Society poster
Using statistical modelling, Dr Chichagova was able to improve the differentiation outcome of human induced pluripotent stem cells to retinal organoids, which were subsequently successfully tested with a toxicologically relevant test compound. As…
Read update
British Toxicological Society Annual Congress 2018 – Hilton Gateshead (16th-18th April)
Hilton Gateshead – 16th-18th April https://www.thebts.org/bts-annual-congress-2018/ The Newcells Biotech team will be attending the British Toxicological Society Annual Congress 2018 that is taking place in Gateshead on 16th-18th April. Newcells Biotech staff…
Read update
Newcells Biotech joins StemBANCC consortium
Newcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups. StemBANCC’s goal is to generate 1,500 iPSC lines from 500 people,…
Read update
NB to develop a new skin metabolism model using iPSC derived skin cells
Working with academics Prof Mark Birch-Machin and Dr Peter Hanson from the Institute of Cellular Medicine, Newcells is using its expertise in cellular reprogramming and differentiation of iPSCs to…
Read update
NB completes a licensing agreement with ID Pharma Co. Ltd for induced pluripotent stem cell technologies
The agreement will enable Newcells to develop, manufacture, distribute products and offer services to customers based on reprogramming cells using the CytioTuneTM-iPS kit. Prof Lyle Armstrong, CSO of Newcells Biotech,…
Read update
NB completes a licensing agreement with iPS Academia Japan, Inc. for induced pluripotent stem cell technologies
The agreement will enable Newcells to develop, manufacture, distribute products and offer services to customers in the pharmaceutical, biotechnology and academic sectors in Europe. Dr Mike Nicholds CEO of Newcells…
Read update
